Outcomes of Left Bundle Branch Area Pacing for Cardiac Resynchronization Therapy: An Updated Systematic Review and Meta-analysis

Jian Liang Tan, MD,a Justin Z. Lee, MBBS,b Vittorio Terrigno, MD,c Benjamin Saracco, MLS, MAIT,d Shivam Saxena, MD,a Jonathan Krathen, DO,a Krystal Hunter, MBA,e Yong-Mei Cha, MD,b and Andrea M. Russo, MDa

a Division of Cardiovascular Disease, Cooper University Health Care/Cooper Medical School of Rowan University, Camden, New Jersey, USA
b Department of Cardiovascular Disease, Mayo Clinic Rochester, Rochester, Minnesota, USA
c Department of Internal Medicine, Cooper University Health Care/Cooper Medical School of Rowan University, Camden, New Jersey, USA
d Research and Digital Services, Cooper Medical School of Rowan University, Camden, New Jersey, USA
e Cooper Research Institute, Cooper Medical School of Rowan University, Camden, New Jersey, USA

Left bundle branch area pacing (LBBAP) for CRT

Follow-up

LBBAP group has greater improvement in:

- QRSd (msec), at 6-12 months
  (MD: 27.91 msec; 95% CI: 22.33-33.50)
- LVEDD (mm), at 6-12 months
  (MD: 3.03 mm; 95% CI: 0.07-5.99)
- LVEF (%), at 6-12 months
  (MD: 6.77; 95% CI: 3.84-9.71)
- NYHA class, at 6-12 months
  (MD: 0.59; 95% CI: 0.28-0.90)
vs BVP group

Overall LBBAP success rate: 86.6%
Biventricular pacing (BVP) as a method of cardiac resynchronization therapy (CRT) has a well-established clinical record, with numerous clinical trials showing clinical benefits in improving functional capacity and quality of life, as well as reducing mortality and rehospitalizations in patients with heart failure with reduced ejection fraction (HFrEF) and a wide QRS complex, especially left bundle branch (LBB) block (LBBB). BVP provides CRT via nonphysiological fusion of paced wave fronts. Therefore, BVP is not truly "physiologic" in that intrinsic conduction is not restored and thus, might not deliver the full potential of ventricular resynchronization. BVP is sometimes limited by implant failure due to unfavourable coronary venous anatomy. Approximately one-third of the patients who received BVP might be classified as CRT nonresponders for a variety of reasons.

His bundle pacing (HBP) was first reported by Deshmukh et al. It aimed to restore physiological activation of the ventricles via the native His-Purkinje system. Although numerous studies have shown the clinical benefits of HBP in patients with HFrEF, concerns regarding high pacing threshold, lead instability, damage to the His bundle, and long-term performance and safety issues have limited its widespread use. Hence, there has been increased interest to explore other physiological pacing techniques.

LBB area pacing (LBBAP) has recently emerged as an alternative novel method for delivering physiological ventricular pacing to capture the left-sided conduction system. Real-world data on the use of LBBAP as an alternative CRT to BVP remains scarce. One prospective study by Huang et al. showed that LBBAP could be an effective technique for CRT in patients with BVP indications. Several other studies have shown that LBBAP provides an electrical and left ventricular mechanical synchrony comparable to HBP. Hence, we conducted an updated systematic review and meta-analysis of the existing literature to evaluate the short-term clinical outcomes of LBBAP as CRT, and compared with BVP.

**Methods**

A systematic literature search was planned and performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for systematic review. Methods of the systematic review and meta-analyses and the inclusion and exclusion criteria were prespecified and are documented in the protocol registered on the International Prospective Register of Systematic Reviews (PROSPERO) (registration number CRD4202013814). The institutional review board review was exempt because of the nature of the study.

**Search strategy**

We searched for publications on LBBAP published from PubMed, EMBASE, and Cochrane Central Register of Controlled Trials between the database inception and December 31, 2020. After consulting with a clinical information specialist, we searched for articles using a combination of main search terms ("left bundle OR left bundle branch OR left
bundle branch area OR heart ventricles”) AND (“pacing OR cardiac pacing”) as either key words or medical subject heading terms. Additional searching for grey literature was conducted in the Web of Science and keyword searching was conducted in Google Scholar. No language or study type restriction was applied. Complete search strategies are available in Supplemental Appendix S1.

Eligibility criteria

Articles that reported LBBAP were reviewed. Studies that reported LBBAP implantation with CRT indication as stated in Table 1 were included in this meta-analysis. Studies that enrolled patients without CRT indications were excluded. Case reports, review articles, editorials, letters, and studies with fewer than 5 patients were excluded. Abstracts presented at conferences that were not published as full reports were also excluded.

Data extraction and appraisal

Rayyan QCRI, a Web-based and smartphone screening application developed by the Qatar Computing Research Institute (Doha, Qatar), was used to screen the articles after duplicates were removed using the Systematic Review Assistant DeDupe-UI software developed by the Bond University Institute for Evidence-Based Health Care. Two reviewers (J.L.

| Table 1. Characteristics of included studies |
|---------------------------------------------|
| Reference | Design | Comparative type | Indication for CRT-D/CRT-P | N | LBBAP | BVP | Follow-up, months |
|---------------------------------------------|--------|------------------|-----------------------------|---|-------|-----|-------------------|
| Wang et al. | Prospective, single-centre | LBBAP vs BVP | Sinus rhythm, LBBB defined by Strauss criteria, NYHA functional class II-IV with LVEF ≤ 50%, NYHA functional class II-IV with LVEF ≥ 50%, nonischemic cardiomyopathy | 40 | Primary LBBAP, n = 10 | Primary BVP, n = 10 | 6 |
| Li et al. | Prospective, observational, multicentre | LBBAP vs BVP | Symptomatic heart failure with LVEF ≤ 35 with LBBB, and had received ≥ 4 months GDMT for HFrEF | 91 | Primary LBBAP, n = 25 | Rescue LBBAP, n = 15 | 6 |
| Wu et al. | Retrospective, single-centre | LBBAP vs BVP | LBBB defined according to Strauss criteria, symptomatic heart failure with LVEF ≤ 40% | 86 | Primary LBBAP, n = 32 | Rescue LBBAP, n = 21 | 12 |
| Guo et al. | Prospective, observational, single-centre | LBBAP vs BVP | LBBB defined according to Strauss criteria, NYHA functional class II-IV with LVEF ≤ 50% | 45 | Primary LBBAP, n = 24 | Primary BVP, n = 21 | 6 |
| Li et al. | Prospective, observational, single-centre | LBBAP only | NYHA functional class II-IV with LVEF < 50% (LBBB, n = 14; RBBB, n = 3; IVCD, n = 4; RVP, n = 4) | 25 | Primary LBBAP, n = 20 | NA | Mean 9.1 ± 5.1 |
| Vijayaraman et al. | Retrospective, observational, multicentre | LBBAP only | NYHA functional class II-IV, baseline LVEFs ≤ 50%, and indications for ventricular pacing and/or CRT (LBBB, n = 126; RBBB, n = 54; IVCD, n = 49; RVP, n = 48, narrow, n = 48) | 325 | NA | NA | Mean 6 ± 5 |
| Huang et al. | Prospective, observational, multicentre | LBBAP only | Complete LBBB, nonischemic cardiomyopathy, symptomatic heart failure with LVEF < 50% | 63 | Rescue LBBAP, n = 65 | NA | Mean 18 (range, 15 to 20) |
| Zhang et al. | Prospective, observational, single-centre | LBBAP only | Symptomatic heart failure with LVEF ≤ 40 with LBBB, and had received ≥ 3 months GDMT for HFrEF | 11 | Primary LBBAP, n = 11 | NA | Mean 6.7 ± 3.3 |

BVP, biventricular pacing; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy defibrillator; CRT-P, cardiac resynchronization therapy pacemaker; GDMT, guideline directed medical therapy; HBP, His bundle pacing; HFrEF, heart failure with reduced ejection fraction; IVCD, intraventricular conduction delay; LBBAP, left bundle branch area pacing; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; NA, not applicable; NYHA, New York Heart Association; RBBB, right bundle branch block; RVP, right ventricular pacing.

*Procedure attempted as the first option in place of coronary sinus left ventricular lead.

1Procedure attempted because of failed coronary sinus left ventricular lead placement.

1Primary or rescue biventricular pacing data were not reported.

1Procedure attempted because of failed HBP lead placement.
T. and V.T.) independently reviewed all titles and abstracts. A third reviewer (A.M.R.) resolved any discrepancies. Full text of potential studies were manually searched and further analyzed to see if they met our eligibility criteria (Fig. 1). We systematically reviewed 8 original research papers, which included 686 patients across multiple centres in the United States, China, Spain, India, Brazil, and Poland. These studies reported outcomes of LBBAP as an alternative pacing modality for delivering CRT. We extracted characteristics of each study, including study name, sample size of the LBBAP group with underlying LBBB and non-LBBB, and BVP group, baseline patient characteristics (age, sex, race/ethnicity, and comorbidities), duration of follow-up, procedural characteristics (average procedural and fluoroscopic time), pacing parameters (paced QRS duration, capture threshold, R-wave amplitude, and impedance), and safety outcomes.

Outcomes

The primary outcomes of this study included changes in the following: (1) QRS duration post CRT device implantation; (2) LV end-diastolic diameter (LVEDD); (3) New York Heart Association (NYHA) classification; and (4) LV ejection fraction (LVEF). Other outcomes of interest included the
average procedural and fluoroscopic time, echocardiographic (LV end-systolic diameter, LV end-diastolic volume (LVEDV), LV end-systolic volume; LVESV) outcomes, pacing characteristics (capture threshold, R-wave amplitude, impedance), and acute procedural-related issues. We performed a separate analysis on the clinical outcomes of LBBAP for CRT in LBBB and non-LBBB patients.

Quality assessment

We used the Newcastle Ottawa Quality Assessment Scale to assess the risk of bias and quality of the studies with a control group. Studies without a control group were assessed using the Standard Quality Assessment Criteria for Evaluating Primary Research Papers from a Variety of Fields. Details of how these were performed are shown in Supplemental Tables S1 and S2. Two authors independently assessed the quality of the articles. A third reviewer resolved any disagreements.

Statistical analysis

Statistical analysis was performed using Review Manager (RevMan Version 5.4, The Cochrane Collaboration, 2020, Oxford, United Kingdom) and STATA software version 16 (StataCorp, College Station, TX). For the primary analysis, individual studies were treated as a random variable. Hence, random effect models were used to assess pooled effect size from aggregate data. For continuous outcomes, pooled effect estimates were calculated by comparing the change from baseline to study end for each group (LBBAP and BVP groups). The mean difference (MD) and 95% confidence interval (CI) for each outcome were calculated and graphically presented using Forest plots. The $I^2$ statistic was used to measure heterogeneity across the studies attributable to the difference between studies rather than chance. $P$ values of < 25%, 25%-50%, and > 50% were considered low, moderate, and high amounts of heterogeneity, respectively. Funnel plots were used to visually estimate for potential publication bias. The baseline characteristics of the studies were tested for the proportions using the proportion calculator. All the tests were 2-sided and a $P$ value < 0.05 was considered statistically significant.

Results

Patient population

Overall, 8 studies, with a total of 527 patients who underwent LBBAP for CRT and 159 patients who underwent BVP, fulfilled the inclusion criteria and were included in the meta-analysis. The PRISMA diagram is shown in Figure 1.

Table 1 shows a summary of the study characteristics of the 8 included studies. Five of the studies were single-centre studies and the remaining of them were multicentre studies. Six were prospective studies and 2 were retrospective studies. Among the included studies, only 4 studies had comparative treatment groups, with 3 studies that compared LBBAP with BVP and 1 study that compared LBBAP with BVP and HBP. Because there was only 1 study that compared the LBBAP group with the HBP group, the result of the HBP group was not included in our data analysis. The remaining 4 studies without the comparative group investigated the outcomes of LBBAP in patients with CRT indicators.

Table 2 shows the overall baseline characteristics of the total population with LBBAP. The mean age was 68 years. On average, men accounted for 61% of the included subjects. Most of the subjects had nonischemic cardiomyopathy (69.2%). The mean QRS duration was 159.98 ± 29.12 msec and the mean LVEF was 31.84 ± 10.35%.

Table 2 shows the baseline clinical characteristics of the 4 studies that compared LBBAP with BVP. Many of these characteristics were comparable between the LBBAP and BVP groups, including age, sex, and comorbidities. Most subjects had nonischemic cardiomyopathy in both groups (89.0% vs 86.8%; $P = 0.60$). Of note, the BVP group had significantly larger mean LVEDD (69.14 ± 6.05 vs 66.31 ± 7.68; $P = 0.01$) and LVESV (158.63 ± 58.37 vs 136.16 ± 50.90; $P = 0.04$) compared with the LBBAP group. Although not statistically significant, the BVP group had larger mean LVEDV (220.05 ± 69.89 vs 195.30 ± 58.42 mL; $P = 0.06$) and lower mean LVEF (28.34 ± 5.53 vs 29.71 ± 6.09%; $P = 0.06$) compared with the LBBAP group. Most of the subjects also received guideline-directed medical therapy with $\beta$-blockers, angiotensin- converting enzyme inhibitor/angiotensin II receptor blocker, and aldosterone antagonist for the treatment of HF+EF before the procedure, without differences between the LBBAP and BVP groups. There were significantly more subjects in the BVP group taking diuretics (99.4% vs 95.0%; $P = 0.02$) compared with the LBBAP group.

Implantation procedure

It is important to note that there was heterogeneity in the criteria used to confirm LBB capture. All 8 studies used paced right bundle branch block morphology in lead V1 with...
Table 3. Baseline characteristics of populations with comparison groups

| Baseline characteristics | LBBAP* | BVP | \( p \) |
|--------------------------|--------|-----|-------|
| Mean age ± SD, years     | 62.88 ± 11.67 | 63.54 ± 10.07 | 0.63 |
| Male, n (%)              | 54 (54.0) | 79 | 0.26 |
| Hypertension, n (%)      | 35 (38.9) | 50 | 0.74 |
| Diabetes mellitus, n (%) | 26 (28.9) | 34 | 0.68 |
| AF, n (%)                | 17 (18.9) | 23 | 0.83 |
| ICM, n (%)               | 11 (11.0) | 20 | 0.70 |
| NICM, n (%)              | 89 (89.0) | 139 | 0.60 |
| Mean NYHA class ± SD     | 2.96 ± 0.65 | 2.95 ± 0.68 | 0.91 |
| Mean QRSd ± SD, ms       | 172.08 ± 18.04 | 170.70 ± 24.03 | 0.64 |
| Mean LVEF ± SD, %        | 29.71 ± 6.09 | 28.34 ± 5.53 | 0.06 |
| Mean LVESD ± SD, mm      | 66.31 ± 7.68 | 69.14 ± 6.05 | 0.01 |
| Mean LVESV ± SD, mL      | 136.16 ± 50.90 | 158.63 ± 58.37 | 0.04 |
| Mean LVEDV ± SD, mL      | 195.30 ± 58.42 | 220.05 ± 69.89 | 0.06 |
| Mean LAD ± SD, mm        | 44.36 ± 5.99 | 46.13 ± 6.08 | 0.69 |

ACEi, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; BVP, biventricular pacing; ICM, ischemic cardiomyopathy; LAD, left atrial diameter; LBBAP, left bundle branch area pacing; LVESD, left ventricular end-diastolic diameter; LVEDD, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; NICM, nonischemic cardiomyopathy; NYHA, New York Heart Association; QRSd, QRS duration.

*Analysis of patients from studies with a comparison group of LBBAP and BVP.

** Procedural complications

The procedural complications in patients with LBBAP included acute lead dislodgment (8 cases), transient complete heart block (5 cases), pneumothorax (3 cases), loss of left septal capture (2 cases), and device infection (2 cases). No other acute procedural complications (septal perforation, pericardial effusion, stroke, tricuspid regurgitation, or vascular injuries) were noted in these studies.

Follow-up: rehospitalization and mortality

During 6-12 months of follow-up, 17 of 467 patients (3.6%) who received LBBAP were hospitalized with acute heart failure and 11 of 467 patients (2.4%) died (all-cause mortality). Four of 159 patients (2.5%) who received BVP experienced heart failure hospitalization, and 2 of 159

BVP, 11,17,18,20,21 Compared with BVP, the average fluoroscopic exposure time of the LBBAP procedure (27.04 ± 16.68 vs 12.48 ± 8.29 minutes; \( P < 0.001 \)), and the average procedural time (122.7 ± 53.5 vs 98.4 ± 36.5 minutes; \( P = 0.03 \)) were significantly shorter. The LBBAP group was associated with significantly lower capture threshold at implantation (0.59 ± 0.26 vs 1.07 ± 0.59 V; \( P < 0.001 \)) and at 6-12 month follow-up (0.63 ± 0.23 vs 1.21 ± 0.66 V; \( P < 0.001 \)) compared with the BVP group; although pulse widths varied at testing in the LBBAP group (0.4-0.5 ms).

Only 4 studies reported the procedural success rate of LBBAP implantation as shown in Table 1. Sixty of 449 subjects (13.4%) had unsuccessful LBBAP procedures. Thirty-three of them were because of an inability to capture the LBB system, 26 were because of failure to penetrate into the interventricular septal at the target site, and 1 had repeated recurrent ventricular tachycardia by pacing the LBB area during the pacing test. Nine of the subjects who had failed LBBAP attempts received BVP, 2 of the subjects received epicardial LV lead implantation, 1 of the subjects received a single-chamber implantable cardioverter defibrillator, and the remaining 48 subjects did not have end points specified.

** Procedure duration and success**

Table 4 shows the overall procedure, echocardiographic, and pacing characteristics of studies with LBBAP (all patients). 9,11,17-19,21,22 The average procedural time was 105.70 ± 51.13 minutes. The mean LVEF at 6-12 months follow-up was 46.61 ± 11.32%. The mean capture threshold at implantation and follow-up were 0.60 ± 0.28 V and 0.67 ± 0.27 V, respectively.

Table 5 shows the procedure, echocardiographic, and pacing characteristics of studies that compared LBBAP with
patients (1.3%) were classified as non-BVP responders. No deaths were reported in the BVP group.

Outcomes of LBBAP vs BVP groups

Effect on paced QRS duration. Pooled analysis from the 4 studies showed a significant difference in a mean reduction of paced QRS duration in the LBBAP group vs BVP group (MD, 27.91 msec; 95% CI, 22.33-33.50 msec; \( P < 0.001; \hat{I}^2 = 0\%) as shown in Figure 2A.\(^{11,17,18,21}\) Only 1 study compared the LBBAP group with the HBP group, and there was no significant difference in mean reduction of paced QRS duration between them (MD, −5.10 msec; 95% CI, −12.34 to 2.14; \( P = 0.170\)).\(^{11}\)

Effect on LVEDD. Pooled analysis from the 3 studies showed a significant difference in a mean reduction of LVEDD in the LBBAP group vs BVP group (MD, 3.03 mm; 95% CI, 0.07-5.99; \( P = 0.04; \hat{I}^2 = 0\%\) as shown in Figure 2B.\(^{11,17,18,21}\)

Effect on NYHA. Pooled analysis from the 4 studies showed that LBBAP was associated with a significantly greater improvement in NYHA classification compared with BVP at 6-12 months follow-up (MD, 0.59; 95% CI, 0.28-0.90; \( P = 0.001; \hat{I}^2 = 40\%; \text{Fig. 2C}.\)\(^{11,17,18,21}\) There was no significant difference in mean improvement of NYHA classification at 12 months follow-up between the HBP and LBBAP groups in the 1 study in which this was evaluated (MD, −0.10; 95% CI, −0.45 to 0.25; \( P = 0.58\)).\(^{11}\)

Effect on LVEF. Pooled analysis from the 4 studies showed that LBBAP was associated with a significantly greater improvement in LVEF compared with BVP at 6-12 months follow-up (MD, 0.59; 95% CI, 0.28-0.90; \( P = 0.001; \hat{I}^2 = 0\%\); \text{Fig. 2D}.\(^{11,17,18,21}\) There was no significant difference in mean improvement of LVEF between the HBP and LBBAP groups (24.0 ± 10.9% vs 23.9 ± 11.7%; \( P = 0.977\)) in the 1 study in which this was evaluated.\(^{11}\)

Outcomes of LBBAP as CRT in the LBBB group

Figure 3 shows the clinical outcomes of LBBAP as CRT in patients with LBBB.\(^{9,11,17-22}\) In patients with LBBP, pooled analysis showed that LBBAP significantly improved their QRS duration (MD, 50.04 msec; 95% CI, 42.25-57.83 msec; \( P < 0.001; \hat{I}^2 = 86\%\), NYHA class (MD, 1.47; 95% CI, 1.27-1.67; \( P < 0.001; \hat{I}^2 = 76\%\), and LVEF (MD, −22.05%; 95% CI, −22.05 to −15.41; \( P < 0.001; \hat{I}^2 = 78\%\) compared with baseline. Table 6 shows there was significant improvement in LVEDD, left ventricular end-systolic diameter, LVEF, and LVEDV compared with baseline in patients with underlying LBBB who received LBBAP as CRT.

Outcomes of LBBAP as CRT in LBBB vs Non-LBBB

Pooled analysis from 2 studies showed a borderline significant difference in mean reduction of paced QRS duration (MD, 20.77 msec; 95% CI, −0.40 to 41.93 msec; \( P = 0.05; \hat{I}^2 = 71\%\), and improvement in LVEF (MD, 6.00%; 95% CI, 0.15-11.84%; \( P = 0.04; \hat{I}^2 = 44\%\)) in patients with underlying LBBB vs patients with underlying non-LBBB (Fig. 4).\(^{17,20}\)

Quality assessment and publication bias

Quality assessment of the individual studies determined that 8 of the included studies were of good quality with a low risk of bias. Details of the quality assessment of the studies are shown in Supplemental Tables S1 and S2. There was no publication bias according to visual assessment of the funnel plots for the selected outcomes of reduction in paced QRS duration, reduction in LVEDD, NYHA improvement, and LVEF improvement (Supplemental Fig. S1).

Discussion

The results of our meta-analysis showed that: (1) LBBAP was capable of delivering physiological pacing with a significantly narrower paced QRS duration in patients with LBBB and HFrEF.
compared with BVP; (2) LBBAP results in an improvement in the LVEDD, LVEF, and NYHA class compared with baseline, and might have at least a similar benefit to BVP in a nonrandomized group of patients studied; (3) LBBAP results in a greater mean reduction in paced QRS duration and mean improvement in LVEF in the LBBB group compared with the non-LBBB group; and (4) there was a low rate of device- or lead-related issues at the time of implantation and during short-term follow-up in small, nonrandomized studies.

To our knowledge, it was Zhong et al. who reported the first systematic review and meta-analysis of LBBAP for CRT.\(^\text{12}\) The authors performed pooled analysis from 6
studies, which examined the clinical outcomes of LBBAP for CRT in 174 patients with LBBB and HFrEF. In our updated systematic review and meta-analysis of 8 nonrandomized studies, we examined the clinical outcomes of LBBAP from a pool of 527 patients with CRT indications.9,11,17-22 In contrast to Zhong et al., in our study we reported a detailed analysis on the clinical outcomes of QRS duration, LVEDD, LVEF, and NYHA class from the 4 studies with comparison groups (between the LBBAP and BVP groups).11,17,18,21 We also performed a pooled analysis from the 8 studies on the clinical outcomes of LBBAP for CRT in patients with LBBB.

Furthermore, we also performed a pooled analysis from the 2 studies on the clinical outcomes of LBBAP for CRT in patients with non-LBBB.19,20 To our knowledge, this is by far the single largest and most comprehensive meta-analysis on LBBAP for CRT to date.

Huang et al. first reported a successful direct LBBAP in a patient with HFrEF and LBBB in the literature as a rescue pacing modality after the failure of CS and His-lead placement.23 The patient had a remarkable clinical improvement in LVEF by 30% and NYHA functional class from a baseline IV to I. Chen et al. further reported successful correction of...

Figure 3. Forest plot of standardized mean difference in reduction in QRS duration, NYHA improvement, and LVEF improvement in patients with underlying LBBB. (A) Reduction in paced QRS duration. (B) NYHA improvement. (C) LVEF improvement. CI, confidence interval; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
LBBB by LBB capture in 2 patients with dilated cardiomyopathy, in which 1 of the patients had a significant improvement in LVEF from 39% at baseline to 49% at 1-year follow-up.24 In an electromechanistic study, Hou et al. reported that LBBAP generated comparable if not favourable electromechanical LV synchrony and hemodynamic effects compared with HBP.10 These observations are hypothesis-generating and have important implications on the potential use of LBBAP in patients who meet the criteria for CRT. The results of this meta-analysis further support the use of LBBAP as an alternative rescue CRT in patients with failed CS-LV lead implantation or CRT nonresponders. However, large randomized controlled trials (RCTs) on the effect of LBBAP with BVP will be necessary to determine the long-term clinical benefits of LBBAP in this population.

Our pooled analysis showed an overall average LBBAP implantation success rate of 86.6% (389/449). As noted by Li et al.17 and Huang et al.9 the operators had significant experience in LBBAP implantation. Hence, the high procedural success rates might not translate to represent the real-world experience. Failure of LBBAP implantation in the pooled studies was mainly because of the inability to capture the LBB conduction system. Further advances and modifications in delivery sheaths and lead design might help to optimize LBBAP and improve the procedural success rate. In a study by Padala et al., the acute success rates of LBBAP implantation was reported at 87% during the first half of the experience.25 As the operators gained more experience, the latter half of the LBBAP group had success rates of 91%.25 There is a significant learning curve to mastering the LBBAP implantation technique. Overall, the implantation success rates of LBBAP remained high, which has been reported to be 89%-94% in the literature.25-28

In our pooled analysis, the LBBAP group had a significantly lower pacing threshold to achieve LBBB correction compared with the capture threshold in the BVP group (0.59 ± 0.26 V vs 1.07 ± 0.59 V; P < 0.001). The pacing thresholds of the LBBAP group remained relatively stable at 6-12 months follow-up. The data on pacing thresholds in the BVP group are consistent with previous CRT studies.29,30 The relatively higher pacing thresholds in patients with BVP could be attributed to differences in local scar burden in the lateral LV wall or epicardial fat compared with the septal

Table 6. Echocardiographic outcomes of LBBAP in patients with underlying LBBB

| Variable          | Baseline Value | Baseline n | Follow-up Value | Follow-up n | P*  |
|-------------------|----------------|------------|-----------------|-------------|-----|
| LVEDD, mm         | 61.15 ± 9.09   | 255        | 54.61 ± 8.63    | 254         | < 0.001 |
| LVESD, mm         | 52.38 ± 9.24   | 88         | 38.73 ± 9.71    | 88          | < 0.001 |
| LVEDV, mL         | 183.80 ± 74.45 | 212        | 142.13 ± 68.82  | 212         | < 0.001 |
| LVESV, mL         | 125.59 ± 60.32 | 212        | 76.26 ± 49.90   | 212         | < 0.001 |

Data are presented as mean ± SD, except where otherwise noted. Subgroup analysis of patients with underlying LBBB who had successfully underwent for LBBAP.

LBBAP, left bundle branch area pacing; LBBB, left bundle branch block; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; LVESD, left ventricular end–systolic diameter; LVESV, left ventricular end-systolic volume.

*Analysis of patients from studies with underlying LBBB at baseline and follow-up.

Figure 4. Forest plot of standardized mean difference in reduction in paced QRS duration and LVEF improvement in LBBB vs Non-LBBB groups. (A) Reduction in paced QRS duration. (B) LVEF improvement. CI, confidence interval; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction.
myocardium in patients who meet CRT indication. A lower pacing threshold could potentially translate into longer device longevity.

Of note, the average procedural and fluoroscopic times were significantly shorter for the LBBAP group compared with the BVP group. This is likely because of direct myocardial contact with an active fixation lead and less anatomical limitation to the CS vasculature. The anatomy of CS might be distorted in dilated hearts. Thus, this might account for the increase in time taken and the use of radiographs to place the CS lead into the target branch vessel.

**Study limitations**

The included studies are prospective and retrospective observational studies because, to our knowledge, there is no RCT to date on the effect of LBBAP in patients with CRT indications. It is important to note that in our meta-analysis we only examined the use of LBBAP in a limited CRT population. This CRT population might not be a standard cohort because it included a large proportion of nonischemic (62.9%) patients as shown in Table 2. So far, there are only 4 non-RCT studies available in the literature that have comparing the effect of LBBAP with BVP in patients with a CRT indication. Hence, generalizability of the results remains difficult.

Known and unknown confounders affect observational studies. As noted in our data analysis (Table 3), the selection criteria for LBBAP and BVP are not uniform. Compared with the LBBAP group, the BVP group had a trend toward a lower baseline LVEF, and larger baseline LVEDD and LVESV. The BVP group were also more likely to receive diuretic therapy. Hence, the BVP group might have been “sicker” than the LBBAP group. Thus, RCTs with uniform patient selection criteria are required to reduce these confounders. Of note, the data included in our systematic review and meta-analysis are not patient-level data. Hence, we were unable to analyze any potential confounding factors and patient selection bias that could potentially affect the clinical outcomes between treatment groups.

Although the implantation success rates of LBBAP are close to 87%, experienced operators performed most of the LBBAP device implantations. Most of the included subjects had nonischemic cardiomyopathy. In addition, these studies did not assess hard clinical outcomes such as heart failure hospitalizations and long-term mortality. The short follow-up periods limit the ability to assess the long-term benefits of physiological pacing of the LBBAP device, the effects of LBBAP on right ventricular function, and potential long-term lead and/or device malfunction. Thus, adequately powered RCTs from multicentre studies are required to assess the long-term clinical benefits of LBBAP and to ensure the generalizability of the results around the globe.

**Conclusion**

The results of this meta-analysis show that LBBAP, as an alternative CRT, is safe, feasible, and appears effective in limited, small, nonrandomized studies. However, large prospective RCTs that compare LBBAP with BVP and have long-term follow-up are required to better characterize the use of this novel pacing strategy in a cardiomyopathy population with LBBB and HFrEF to investigate potential indications and populations that might benefit the most from LBBAP.

**Acknowledgements**

We sincerely thank Dr Yee Liong Lee for assistance with the illustration.

**Funding Sources**

The authors report no funding sources.

**Disclosures**

Andrea M. Russo discloses research trials, funding to hospital (Boston Scientific, Kestra, Medilynx), research steering committee (Boston Scientific, Medtronic), and consultant ( Biosense Webster, Boston Scientific, Medtronic).

All other authors have no conflicts of interest to disclose.

**References**

1. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008;117:e350–408.

2. Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. J Card Fail 2000;6:276–85.

3. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539–49.

4. Jarcho JA. Biventricular pacing. N Engl J Med 2006;355:288–94.

5. Daubert C, Behar N, Martins RP, Mabo P, Leclercq C. Avoiding non-responders to cardiac resynchronization therapy: a practical guide. Eur Heart J 2017;38:1463–72.

6. Deshmukh P, Casavant DA, Romanyshyn M, Anderson K. Permanent, direct His-bundle pacing: a novel approach to cardiac pacing in patients with normal His-Purkinje activation. Circulation 2000;101:869–77.

7. Qian Z, Zou F, Wang Y, et al. Permanent His bundle pacing: a novel approach to cardiac pacing in patients with normal His-Purkinje activation. Circulation 2000;101:869–77.

8. Vijayaraman P, Naperkowski A, Subzposh FA, et al. Permanent His-bundle pacing: long-term lead performance and clinical outcomes. Heart Rhythm 2018;15:696–702.

9. Huang W, Wu S, Vijayaraman P, et al. Cardiac resynchronization therapy in patients with nonischemic cardiomyopathy using left bundle branch pacing. JACC Clin Electrophysiol 2020;6:849–58.

10. Hou X, Qian Z, Wang Y, et al. Feasibility and cardiac synchrony of permanent left bundle branch pacing through the interventricular septum. Europace 2019;21:1694–702.
11. Wu S, Su L, Vijayaraman P, et al. Left bundle branch pacing for cardiac resynchronization therapy: nonrandomized on-treatment comparison with His bundle pacing and biventricular pacing. Can J Cardiol 2021;37:319–28.
12. Zhong C, Xu W, Shi S, Zhou X, Zhu Z. Left bundle branch pacing for cardiac resynchronization therapy: a systematic literature review and meta-analysis. Pacing Clin Electrophysiol 2021;44:497–505.
13. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
14. Tan JL, Lee JZ, Terrigno V, et al. Impact of left bundle branch area pacing among patients with cardiac resynchronization therapy indication: a systematic review and meta-analysis. Available at: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=213814. Accessed May 30, 2021.
15. Wells GA, Shea B, Higgins JP, et al. Checklists of methodological issues for review authors to consider when including non-randomized studies in systematic reviews. Res Synth Methods 2013;4:63–77.
16. Institute of Health Economics. Alberta Canada. Standard quality assessment criteria for evaluating primary research papers from a variety of fields. Alberta Heritage Foundation for Medical Research (AHFMR) HTA Initiative #13. Available at: https://www.ihe.ca/advanced-search/standard-quality-assessment-criteria-for-evaluating-primary-research-papers-from-a-variety-of-fields. Accessed May 30, 2021.
17. Li X, Qiu C, Xie R, et al. Left bundle branch area pacing delivery of cardiac resynchronization therapy and comparison with biventricular pacing. ESC Heart Fail 2020;7:1711–22.
18. Wang Y, Gu K, Qian Z, et al. The efficacy of left bundle branch area pacing compared with biventricular pacing in patients with heart failure: a matched case-control study. J Cardiovasc Electrophysiol 2020;31:2068–77.
19. Zhang W, Huang J, Qi Y, et al. Cardiac resynchronization therapy by left bundle branch area pacing in patients with heart failure and left bundle branch block. Heart Rhythm 2019;16:1783–90.
20. Vijayaraman P, Ponnusamy S, Cano O, et al. Left bundle branch area pacing for cardiac resynchronization therapy: results from the International LBBPAP Collaborative Study Group. JACC Clin Electrophysiol 2021;7:135–47.
21. Guo J, Li L, Xiao G, et al. Remarkable response to cardiac resynchronization therapy via left bundle branch pacing in patients with true left bundle branch block. Clin Cardiol 2020;43:1460–8.
22. Li Y, Yan L, Dai Y, et al. Feasibility and efficacy of left bundle branch area pacing in patients indicated for cardiac resynchronization therapy. Europace 2020;22:i54–60.
23. Huang W, Su L, Wu S, et al. A novel pacing strategy with low and stable output: pacing the left bundle branch immediately beyond the conduction block. Can J Cardiol 2017;33:1736 e1–3.
24. Chen X, Wu S, Su L, Su Y, Huang W. The characteristics of the electrocardiogram and the intracardiac electrogram in left bundle branch pacing. J Cardiovasc Electrophysiol 2019;30:1096–101.
25. Padala SK, Master VM, Terricabras M, et al. Initial experience, safety, and feasibility of left bundle branch area pacing. JACC Clin Electrophysiol 2020;6:1773–82.
26. Vijayaraman P, Cano O, Koruth JS, et al. His-Purkinje conduction system pacing following transcatheter aortic valve replacement: feasibility and safety. JACC Clin Electrophysiol 2020;6:649–57.
27. Vijayaraman P, Subzposh FA, Naperkowski A, et al. Prospective evaluation of feasibility and electrophysiologic and echocardiographic characteristics of left bundle branch area pacing. Heart Rhythm 2019;16:1774–82.
28. Wang J, Liang Y, Wang W, et al. Left bundle branch area pacing is superior to right ventricular septum pacing concerning depolarization-repolarization reserve. J Cardiovasc Electrophysiol 2020;31:313–22.
29. Pires LA, McNitt S, Solomon S, et al. Left ventricular pacing threshold and outcome in MADIT-CRT. J Cardiovasc Electrophysiol 2014;25:1005–11.
30. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344:873–80.

Supplementary Material
To access the supplementary material accompanying this article, visit CJC Open at https://www.cjcopen.ca/ and at doi:10.1016/j.cjco.2021.05.019.